# An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

> **NCT03259633** · — · APPROVED_FOR_MARKETING · sponsor: **AstraZeneca**

## Conditions studied

- NF type1 With Inoperable Plexiform Neurofibromas

## Interventions

- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT03259633
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259633, "An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03259633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*